Schiano Elisabetta, Maisto Maria, Piccolo Vincenzo, Novellino Ettore, Annunziata Giuseppe, Ciampaglia Roberto, Montesano Camilla, Croce Martina, Caruso Giuseppe, Iannuzzo Fortuna, Summa Vincenzo, Tenore Gian Carlo
Department of Pharmacy, University of Naples Federico II, via Domenico Montesano 59, 80131 Naples, Italy.
Department of Medicine and Surgery, Catholic University of the Sacred Heart, 00168 Rome, Italy.
Foods. 2022 Aug 31;11(17):2637. doi: 10.3390/foods11172637.
The control of glucose homeostasis represents the primary goal for the prevention and management of diabetes and prediabetes. In recent decades, the hypoglycemic hormone abscisic acid (ABA) has attracted considerable interest in the scientific literature. In this regard, the high ABA concentration in immature fruits led us to consider these food matrices as candidates for diabetes control. Therefore, the beneficial efficacy of a nutraceutical formulation based on thinned nectarines (TNs) rich in ABA was tested through a three-month, three-arm, parallel-group, randomized controlled trial (RCT) conducted on sixty-one patients with type 2 diabetes (T2D). After 3 months, both the treatments with low doses of TN (500 mg 3 times/day) and high doses of TN (750 mg 3 times/day) showed a significant reduction in glycemic parameters compared to baseline. Treatment with low doses of TN showed a greater insulin-sparing effect (fasting plasma insulin, FPI: −29.2%, p < 0.05 vs. baseline) compared to the high-dose group (FPI: −16.5%, p < 0.05 vs. baseline). Moreover, a significant correlation between glycemia and ABA plasmatic levels was observed for both intervention groups at baseline and after 3 months. Overall, our data reasonably support TN as a promising and innovative nutraceutical product able to contribute to the management of glucose homeostasis.
控制血糖稳态是预防和管理糖尿病及糖尿病前期的主要目标。近几十年来，降血糖激素脱落酸（ABA）在科学文献中引起了相当大的关注。在这方面，未成熟果实中高浓度的ABA使我们将这些食物基质视为控制糖尿病的候选物。因此，通过对61例2型糖尿病（T2D）患者进行的为期三个月、三臂、平行组、随机对照试验（RCT），测试了一种基于富含ABA的疏果油桃（TN）的营养制剂的有益功效。3个月后，低剂量TN（500 mg，每日3次）和高剂量TN（750 mg，每日3次）治疗均显示血糖参数与基线相比显著降低。与高剂量组相比，低剂量TN治疗显示出更大的胰岛素节省效应（空腹血浆胰岛素，FPI：−29.2%，与基线相比p<0.05）（FPI：−16.5%，与基线相比p<0.05）。此外，在基线和3个月后，两个干预组的血糖与血浆ABA水平之间均观察到显著相关性。总体而言，我们的数据合理地支持TN作为一种有前景的创新营养产品，能够有助于血糖稳态管理。
